Healing the Opioid Crisis with Mindfulness-Oriented Recovery Enhancement: Outcomes and Mechanisms of An Evidence-Based Therapy for Chronic Pain, Opioid Misuse, and Addiction enduring module is a recording from the live Regularly Scheduled Series dated May 18, 2023. If you claimed credit for this session at the live meeting, you should not claim credit for this module.

Faculty

Needs Statement

The opioid crisis and chronic pain have been empirically linked to the rising tide of morbidity and mortality (↑ 0.5% a year since 1998) observed among white U.S. adults.  Opioid addiction and chronic pain are diseases of despair fueled by hopelessness and meaninglessness. Mindfulness-oriented Empowerment therapy has been shown through research to be effective, alternative form of therapy for treating addiction, stress, and chronic pain.

Target Audience

Physicians, Nurses, Nurse Practitioners, Physician Assistants, Pharmacists, Social Workers

Objectives

Upon completion of this activity, participants will be able to:

1. Identify two cognitive, affective, and neurobiological mechanisms implicated in substance use disorders, affective disorders, and chronic pain.    
2. Explain three therapeutic techniques to reduce craving, regulate addictive behavior, decrease negative emotions, and/or manage chronic pain. 
3. Describe the clinical outcomes of Mindfulness-Oriented Recovery Enhancement for chronic pain and opioid misuse.

Accreditation

In support of improving patient care, University of Kentucky HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CME
This enduring material is designated for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

This training has been approved by the KBML as meeting the statutory requirements of HB1. 0523-H1.5-UKHC/May23

IPE Competencies

• Values/Ethics for Interprofessional Practice
• Roles/ Responsibilities
• Interprofessional Communication
• Teams and Teamwork

CPE
This knowledge-based activity will award 1.25 contact hours (0.125 CEUs) of continuing pharmacy education credit in states that recognize ACPE providers.

ASWB ACE
As a Jointly Accredited Organization, UK HealthCare CECentral is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. UK HealthCare CECentral maintains responsibility for this course. Social workers completing this course receive 1.25 clinical continuing education credits.

CNE
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.25 nursing contact hours.

Faculty Disclosure

All planners, faculty, and others in control of educational content are required to disclose all their financial relationships with ineligible companies within the prior 24 months. An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company.

None of the planners, faculty, and others in control of educational content for this educational activity have a relevant financial relationship(s) to disclose with ineligible companies.

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include a discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off-label uses.

Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation

Acknowledgement

In collaboration with UK Substance Use Research Priority Area.